

CHINA JSFDA ACCEPTS EISAI'S APPLICATION SEEKING ADDITIONAL INDICATION OF SEVERE ALZHEIMER'S DISEASE FOR ARICEPT

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its New Drug Application for the additional indication of severe Alzheimer's Disease (AD) for Aricept® (donepezil hydrochloride, brand name in China: 安理申®) has been accepted for review by the Jiangsu Food and Drug Administration